Last reviewed · How we verify

ROZANOLIXIZUMAB — Competitive Intelligence Brief

ROZANOLIXIZUMAB (ROZANOLIXIZUMAB) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neonatal Fc Receptor Blocker [EPC].

marketed Neonatal Fc Receptor Blocker [EPC] Monoclonal antibody Live · refreshed every 30 min

Target snapshot

ROZANOLIXIZUMAB (ROZANOLIXIZUMAB).

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ROZANOLIXIZUMAB TARGET ROZANOLIXIZUMAB marketed Neonatal Fc Receptor Blocker [EPC] 2023-01-01
RYSTIGGO ROZANOLIXIZUMAB-NOLI UCB INC marketed Neonatal Fc Receptor Blocker [EPC] IgG receptor FcRn large subunit p51

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neonatal Fc Receptor Blocker [EPC] class)

  1. · 1 drug in this class
  2. UCB INC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ROZANOLIXIZUMAB — Competitive Intelligence Brief. https://druglandscape.com/ci/rozanolixizumab. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: